As often happens in cancer research, a new class of compounds emerges every so often, fades out with various tricky clinical challenges then roars back again anew with target variations on a similar theme, as new data become available.

Most cancer signalling pathways veer towards the complex rather than simple, so can we learn from the past and try again by aiming at different compartments and cells?

Some recent translational data relating to IO and cancer immunotherapy can offer us fresh hope for potential novel combinations, especially with immunotherapies rather than chemotherapies.

The molecule designs have also moved on too thus offering additional opportunities and possibilities, which may not have the same difficulties with the therapeutic window limitations seen a decade ago.

There’s always something new to be hopeful about, so let’s take a look at what new ideas are emerging from the doldrums…

To learn more from our oncology analysis and get a heads up on the latest insights and analysis pertaining to oncology R&D, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by